Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer.

Molecular cancer therapeutics - 1 Apr 2018

Chen Guangming, Gao Chenxi, Gao Xuan, Zhang Dennis Han, Kuan Shih-Fan, Burns Timothy F, Hu Jing

Abstract excerpt

One of the most encouraging developments in oncology has been the success of BRAF inhibitors in BRAF-mutant melanoma. However, in contrast to its striking efficacy in BRAF-mutant melanomas, BRAF inhibitor monotherapy is ineffective in BRAF-mutant colorectal cancer. Although many studies on BRAF inhibitor resistance in colorectal cancer have focused on mechanisms underlying the reactivation of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta Catenin
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Nude

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Tumor Cells, Cultured

Share to Wnt1 Protein

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 29167314
DOI: 10.1158/1535-7163.MCT-17-0561
PMCID: PMC5882543

Genes

BRAF
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer.PMID 29167314Read ↗

Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas.Semantic proximity Read ↗

WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.Semantic proximity Read ↗

Acquired resistance to BRAF inhibitory treatments requires tumor tissue remodeling and reveals targetable vulnerabilities in colorectal cancerSemantic proximity Read ↗

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.Semantic proximity Read ↗

New therapeutic strategies for BRAF mutant colorectal cancers.Semantic proximity Read ↗

WNT Signalling Promotes NF-κB Activation and Drug Resistance in KRAS-Mutant Colorectal CancerSemantic proximity Read ↗

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <i>BRAF</i> -Mutant Colorectal Cancers to RAF Inhibition with VemurafenibSemantic proximity Read ↗

FAK loss reduces BRAFV600E-induced ERK phosphorylation to promote intestinal stemness and cecal tumor formationSemantic proximity Read ↗

Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.Semantic proximity Read ↗

The Crosstalk between FAK and Wnt Signaling Pathways in Cancer and Its Therapeutic ImplicationSemantic proximity Read ↗

<i>BRAF</i> Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E MutationSemantic proximity Read ↗

WNT signalling promotes NF-κB activation and drug resistance in KRAS-mutant colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.